Videos of Mr Simon Monkhouse
How does Allurion's Elipse encourage weight loss? Q&A with Mr. Simon Monkhouse (Series)
Description:
Discover everything about the Elipse Programme: https://allurion.com/en Sometimes, dieting isn’t enough. No weight loss programme is a magic bullet. However, Elipse is a fully supported lifestyle programme. During the programme you will work with your doctor and nutritionist on a food and exercise plan, training yourself to eat smaller portions which may help in the lifestyle transformation of a new you. This will increase the chances of keeping the weight off.** The Elipse Balloon is a revolutionary gastric balloon that creates a feeling of fullness by taking up space in your stomach. It gives you the chance to take a ‘honeymoon from hunger’. (1) The balloon takes up space in your stomach and induces weight loss by increasing the feeling of fullness. This means that you are more likely to reduce the amount of food you eat throughout the day. (2) Lose an average of 10 to 15kg (1.57 to 2.36 stone) during your 16-week placement with support from a nutritionist and our connected app and scale (2 to 12) Results may vary from one patient to another. A small percentage of patients don’t respond to the treatment. *In rare cases, the Elipse Balloon may require endoscopic or surgical intervention for removal. In rare cases, the empty balloon may be vomited instead of passing through the GI tract. 1 Jamal et al. Obes Surg. 2019 Apr;29(4):1236-1241. 2 Raftopoulos and Giannakou. SOARD. 2017 Jul;13(7):1174-1182. 4 Machytka E et al. Endoscopy. 2017 Feb;49(2):154-160. 5 Genco et al. Obes Surg 2017,DOI 10.1007/s11695-017-2877-1 6 Al-Subaie S et al. Int J Surg. 2017 Dec;48:16-22. 7 Ienca et al. Submitted to SOARD. Abstract A278, presented at Obesity Week, 2018, Nashville, USA 8 Genco et al. Abstract A185. Oral Presentation at Obesity Week, 2018, Nashville, USA 9 Ienca et al. Abstract 237, presented at IFSO 2019, Madrid, Spain 10 Raftopoulos et al. Abstract 1978. Presented at ACS 2019, San Francisco, United States 11 Clinical Trial Reports: DAA069 and DAA105 12 Raftopoulos et al. Abstract 1978. Presented at ACS 2019, San Francisco, United States